3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
9
Sarcoma
3
Breast
3
CNS
2
Thoracic
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Magnetic Resonance Spectroscopy
46
Specimen Handling
39
enzalutamide
32
Nivolumab
30
pembrolizumab
29
Gemcitabine
25
Docetaxel
24
apalutamide
20
Prednisone
20
Biopsy
20
Androgen Antagonists
18
Abiraterone Acetate
18
Cisplatin
15
cabozantinib
14
abiraterone
14
Radiotherapy
14
darolutamide
13
enfortumab vedotin
12
Ipilimumab
12
Radiosurgery
11
Radiation
11
Pluvicto
11
belzutifan
10
Mitomycin
10
erdafitinib
9
atezolizumab
9
X-Rays
9
olaparib
8
durvalumab
8
cabazitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Surgical Procedures, Operative
×
Genitourinary
×
30 days
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled